Pharmacokinetics of clofazimine tablet formulation in children with rifampicin-resistant tuberculosis in CATALYST, a multi-site international trial

Clicks: 11
ID: 328139
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #46 of 135 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 135 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
We evaluated the pharmacokinetics of a novel child-friendly 50 mg clofazimine tablet formulation that disperses quickly in water, compared to traditional gel capsules, in 36 children routinely treated for rifampicin-resistant tuberculosis. No substantial pharmacokinetic difference was observed between tablets and gel capsules, supporting the tablet formulation use for paediatric dosing.
Reference Key
openalex_W7212014911 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yuanxi Zou, Megan Palmer, Melchor V G Frias, Dessa Jean O Casalme, Aarti Kinikar, Mandar Paradkar, Vandana Kulkarni, Pragathi Kamath, Ingrid Courtney, Heather Draper, Lubbe Wiesner, Mats O. Karlsson, Paolo Denti, Louvina E. van der Laan, Anthony J. Garcia‐Prats, Anneke C. Hesseling, Elin M. Svensson
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag089
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.